Vascular Pharmacology, published by Elsevier Science Inc, is a leading journal in the fields of pharmacology and molecular medicine, dedicated to advancing our understanding of vascular biology and therapeutic interventions. With an impressive impact factor reflecting its significant contribution to the scientific community, this journal seeks to publish ground-breaking research that elucidates the molecular mechanisms underlying vascular function and disease, as well as the pharmacological impact of new therapeutic agents. The journal operates under a dual access model, allowing for both subscription and open access options, ensuring that vital research is accessible to a wide audience. As of 2023, it holds a prestigious position in the Q1 category for pharmacology and ranks well in molecular medicine and physiology, reflecting its high quality and relevance. Whether you are a researcher, clinician, or student, Vascular Pharmacology serves as an essential resource to stay at the forefront of cardiovascular pharmacotherapy and vascular biology.

Cardiology Journal, published by VIA MEDICA, stands as a prominent resource in the field of cardiology and cardiovascular medicine, with an ISSN of 1897-5593 and an E-ISSN of 1898-018X. Recognized for its Open Access model established since 1994, this journal facilitates widespread dissemination of critical research findings, allowing practitioners and researchers globally to access valuable insights without barriers. Based in Poland, with an address at UL SWIETOKRZYSKA 73, 80-180 GDANSK, it has achieved a respectable Q2 classification in 2023 for both Cardiology and Miscellaneous Medicine categories, reflecting its influence and quality within the scholarly community. With a Scopus ranking placing it at #117 out of 387 in Cardiology, it lies within the 69th percentile, underpinning its commitment to advancing knowledge in cardiovascular health. The journal’s converged years extending from 2006 to 2024 ensure it captures ongoing developments in a rapidly evolving field. As such, the Cardiology Journal serves as an indispensable platform for researchers, professionals, and students dedicated to exploring the frontiers of cardiac science and improving patient care.

CARDIOVASCULAR DRUGS AND THERAPY, published by Springer, is a premier journal dedicated to the latest advances in cardiovascular pharmacology and therapeutics. With a significant impact factor and esteemed rankings in cardiology and pharmacology, this journal is positioned in the top quartile categories, reflecting its influence and contribution to the field. Since its inception in 1987, the journal has served an international audience, providing a platform for researchers and practitioners to publish high-quality original research, critical reviews, and innovative clinical studies that address pressing issues in cardiovascular health. The journal's rigorous peer-review process ensures the utmost scholarly merit, making it an essential resource for professionals aiming to stay at the forefront of cardiovascular drug research and therapy. While not an open-access publication, it is widely available through institutional subscriptions, enhancing its reach within the global community of cardiology researchers and practitioners. Located in the Netherlands, CARDIOVASCULAR DRUGS AND THERAPY continues to play a vital role in advancing our understanding of cardiovascular diseases and the pharmacological solutions available to combat them.

Current Vascular Pharmacology is a premier academic journal published by Bentham Science Publications Ltd, focusing on the intersection of pharmacology and cardiovascular medicine. With an impact factor that reflects its significance in the field, this journal ranks in the Q1 category for both Pharmacology and Cardiology, showcasing its dedication to high-quality research. Its Scopus ranks place it in the top percentile of its categories, highlighting its influence among scholars and practitioners alike. Issued since 2003 and continuing through 2024, Current Vascular Pharmacology aims to disseminate cutting-edge findings and foster knowledge exchange among researchers, professionals, and students engaged in cardiovascular pharmacology. Despite being a subscription-based journal, it remains a vital resource for those seeking the latest advancements in drug development and therapeutic interventions for vascular diseases. Located in the United Arab Emirates, the journal serves as an essential platform for global discourse on vascular health.

Acta Cardiologica Sinica is a distinguished journal dedicated to the advancement of cardiology and cardiovascular medicine, published by the Taiwan Society of Cardiology. Since its inception in 1988, this journal has provided a platform for researchers and clinicians to share cutting-edge findings and insights into cardiac health, cardiovascular diseases, and innovative treatment strategies. With an impressive Q3 classification in the Cardiology category for 2023, the journal is recognized for its contributions to the field, ranked #208 out of 387 in Scopus, placing it within the 46th percentile of medical journals. Although it currently does not offer open access options, it remains a valued resource for the global cardiovascular community. The journal's commitment to disseminating high-quality research papers, reviews, and case studies ensures that it plays a vital role in improving cardiovascular health practices and outcomes. For researchers, professionals, and students alike, Acta Cardiologica Sinica is essential reading for staying informed about the latest developments in cardiology.

Journal of Pharmacological Sciences is a leading peer-reviewed academic journal dedicated to the field of pharmacology, published by the Japanese Pharmacological Society. Since its inception, this journal has offered an essential platform for the dissemination of high-quality research, contributing significantly to advancements in molecular medicine and pharmacology. With an impact factor that places it in the prestigious Q2 quartile for both categories, the journal has established itself as a credible source of innovative findings and methodologies since its transition to Open Access in 2015. This accessibility enables a broader audience, including researchers, healthcare professionals, and students, to engage with valuable insights and discussions pertinent to drug development, pharmacodynamics, and therapeutic strategies. Based in Kyoto, Japan, the journal serves as a vital resource for the global pharmacological community, encouraging collaboration and research that leads to improved health outcomes. For more information, submissions, and access to the latest research, visit the journal’s website.

Journal of the Practice of Cardiovascular Sciences, published by Wolters Kluwer Medknow Publications, is an esteemed Open Access journal dedicated to advancing knowledge in the field of cardiovascular health. With its ISSN 2395-5414 and E-ISSN 2454-2830, the journal serves as a vital platform for researchers, healthcare professionals, and students to disseminate and access high-quality studies, innovations, and practical applications related to cardiovascular sciences. Established in 2015 as an Open Access journal, it promotes widespread sharing of insights to enhance cardiovascular practices and address contemporary challenges in the field. As part of a reputable publishing group, the journal is poised for growth and impact, contributing significantly to the ongoing dialogue in cardiovascular research and clinical practice.

Giornale Italiano di Cardiologia is a premier journal in the field of cardiology, published by PENSIERO SCIENTIFICO EDITORE. Established in 1996, this journal serves as an essential platform for sharing the latest research and clinical advancements in cardiovascular medicine, particularly catering to the Italian and international medical communities. Although currently classified in the Q4 quartile for Cardiology and Cardiovascular Medicine (2023), the journal strives to enhance its impact and outreach by embracing rigorous peer-review practices and promoting high-quality submissions. With a commitment to enriching knowledge and fostering dialogue among researchers, clinicians, and students, the journal offers a collection of articles that include original research, reviews, and case studies. While currently not an Open Access publication, readers will benefit from a wealth of research insights that contribute to advancements in cardiac care and treatment strategies. As the Giornale Italiano di Cardiologia continues to evolve, it plays a vital role in bridging research and clinical practice in the cardiovascular domain.

Clinica e Investigacion en Arteriosclerosis is a premier academic journal dedicated to the field of cardiology and cardiovascular medicine, published by ELSEVIER. With its ISSN 0214-9168 and E-ISSN 1578-1879, the journal aims to disseminate high-quality research and innovations in the understanding and treatment of arterial diseases, contributing significantly to both clinical practices and pharmacological advancements. Established in 2007 and continuing into 2024, the journal has garnered recognition with a notable Q3 categorization in both Cardiology and Cardiovascular Medicine and Pharmacology (medical) for 2023, reflecting its impact in the academic community. Researchers and healthcare professionals utilizing this journal will find a diverse range of articles exploring novel therapeutic strategies and epidemiological data, making it an essential resource for advancing knowledge and practice in cardiovascular health. While it does not operate as an open-access journal, the findings published in Clinica e Investigacion en Arteriosclerosis are pivotal for understanding current trends and future directions in cardiovascular research.

Netherlands Heart Journal is a premier academic publication dedicated to advancing knowledge in the field of cardiology and cardiovascular medicine. Published by BOHN STAFLEU VAN LOGHUM BV, this journal has established itself as a critical platform for researchers, professionals, and students seeking to explore groundbreaking findings and innovative practices in cardiovascular health. With an ISSN of 1568-5888 and E-ISSN 1876-6250, the journal boasts a respectable Q2 ranking in the Cardiology and Cardiovascular Medicine category, placing it in the top half of its field according to the 2023 quartiles. The Scopus ranking places it 130th out of 387 in the relevant category, indicating a commendable percentile rank of 66th, which attests to its influence and quality of published research. Spanning from 2005 to 2024, the journal endeavors to include a diverse array of topics, encompassing clinical practice, technological innovations, and public health considerations related to cardiovascular diseases. Researchers and practitioners are encouraged to engage with the journal's robust content, contributing to and benefiting from the collaborative effort to enhance cardiovascular health worldwide.